

* Asthma :

Asthma: Asthma is a chronic disease characterized by recurrent attacks of shortness of breath and wheezing.

β -blockers \rightarrow asthma \rightarrow worse
 \rightarrow COPD \rightarrow beneficial

severe asthma & bad not controlled, bad day and night symptoms, exacerbations, need steroids \rightarrow 50% of the year (true severe)

uncontrolled asthma & poor control, exacerbations, not necessarily severe (may be uncompliant to medications, environmental exposures)

(if controlled \rightarrow \downarrow severity)

for assessing control of asthma symptoms we use **ACT (asthma control test)** and **ACQ (asthma control questionnaire)**

Pathophysiology

- Airway inflammation **chronic**
 recurrent attacks of symptoms, but between attacks inflammation is there
- Intermittent airflow obstruction
 Contributing factors \rightarrow smooth muscles, mucus secretion, goblet cell hyperplasia, inflammation in submucosa
- Bronchial hyperresponsiveness \rightarrow exaggerated response to environmental allergens

* acute bronchoconstriction \rightarrow airway edema
 airway remodeling \leftarrow chronic mucus plug formation

How do patients with asthma with effect on airway remodeling (lot of fibroblasts in airway) present clinically?
 \rightarrow persistent airway obstruction on PFT (not reversible with bronchodilator)

patient with asthma present to ER, ABG's P_{aCO_2} is normal
 has severe airway obstruction (because I assume if pt. with airway obstruction \rightarrow hyperventilate \rightarrow $\downarrow P_{aCO_2}$)
 asthma pt. $P_{aCO_2} < 35$

* Aspirin induced asthma :

- asthma, aspirin sensitivity, nasal polyps
- manage: aspirin desensitization & leukotriene antagonists (montelukast)

* GERD :

antireflux therapy may improve asthma symptoms

* Occupational :

High-risk jobs: farming, painting, janitorial work, and plastics manufacturing

Peak-flow monitoring during work (optimally, at least 4 times a day) for at least 2 weeks and a similar period away from work is one recommended method to establish the diagnosis.

* Sinusitis :

tx improves asthma

* exercise induced :

- normal resting spirometry
- tx = warm up, β_2 agonists

asthma exacerbation \rightarrow worsening in sympt. leading to change in management
 cough may be the only symptom of asthma

* exacerbations :

- Mild:
 - can talk in sentences and lie down
 - O_2 sat. preserved ($> 95\%$)
- Moderate:
 - use of accessory muscles
 - pulsus paradoxus
 - O_2 sat 91-92%
- Severe:
 - talk in words
 - O_2 sat $< 91\%$

Impending Respiratory Failure

- Drowsy and confused**
- Thoracoabdominal movement
- Wheezing may be absent**

Asthma Differential Diagnoses

- Vocal cord dysfunction or inducible laryngeal obstruction (ILO):** paradoxical adduction of the vocal cords during inspiration, and may disappear with panting, speech, or laughing
 Direct laryngoscopy during symptomatic periods or after exercise
 The presence of flattening of the inspiratory limb of the flow-volume loop may also suggest vocal cord dysfunction, but this is only seen in 28% of patients at baseline!

Asthma Workup

- Blood and sputum eosinophilia:**
 - Greater than 4% (blood) supports the diagnosis of asthma
 - Its absence does not exclude asthma
 - Greater than 8% may be observed in patients with:
 - Atopic dermatitis.
 - Allergic bronchopulmonary aspergillosis.
 - EGPA
 - Eosinophilic pneumonia
 - Use **mepolizumab (anti-IL-5 antibody)** if counts 150 cells/ μ L or an eosinophil count of 300 cells/ μ L within the past 12 months
 - Adjust ICS with sputum eosinophilia
- Serum Immunoglobulin E:**
 - Total serum immunoglobulin E levels greater than 100 IU are frequently observed in patients experiencing allergic reactions
 - Observed also in: (allergic bronchopulmonary aspergillosis, EGPA)
 - Normal levels do not exclude the diagnosis of asthma
 - Elevated levels are required for chronic asthma patients to be treated with **omalizumab (Xolair)**

PFTs


Reversibility: increase of 12% and 200 mL after the administration of a short-acting bronchodilator \rightarrow either in FEV₁ or in FVC

- methacholine challenge test \rightarrow 20% decrease FEV₁
- mannitol " " " " \rightarrow 15% " " " "
- Peak Flow monitoring \rightarrow 20% variability between morning and night

GINA 2023 guidelines:

GINA 2023 – Adults & adolescents 12+ years

Personalized asthma management Assess, Adjust, Review for individual patient needs



TRACK 1: PREFERRED CONTROLLER and RELIEVER	TRACK 2: Alternative CONTROLLER and RELIEVER	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5
Using ICS-formoterol as the reliever* reduces the risk of exacerbations compared with using a SABA reliever, and is a simpler regimen	Before considering a regimen with SABA reliever, check if the patient is likely to adhere to daily controller treatment	As-needed-only low dose ICS-formoterol	Low dose maintenance ICS-formoterol	Low dose maintenance ICS-LABA	Medium dose maintenance ICS-formoterol	Add-on LAMA. Refer for assessment of phenotype. Consider high dose maintenance ICS-formoterol, \pm anti-IgE, anti-IL5/5R, anti-IL4R α , anti-TSLP
RELIEVER: As-needed low-dose ICS-formoterol*		RELIEVER: as-needed ICS-SABA*, or as-needed SABA		RELIEVER: as-needed low-dose ICS-formoterol*		
Other controller options (low evidence for efficacy or safety – see text)		Low dose ICS whenever SABA taken*, or daily LTRA, or add HDM SLIT	Medium dose ICS, or add LTRA, or add HDM SLIT	Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS	Add azithromycin (adults) or LTRA. As last resort consider adding low dose OCS but consider side-effects	

Acute Exacerbation

- Short acting bronchodilators . salbutamol
- Steroids hydrocortisone IV
- Heliox: 80:20 helium + O_2
- Intubation

33- What is the best test used for the evaluation of the severity of an asthma attack?

- a. FEV1
- b. FVC
- c. PEF **peak exp flow**
- d. PIF
- e. DLCO

Answer: C